What Are the Different Cyclophosphamide Side Effects?

Ifosfamide for injection, testicular tumors are used in combination with chemotherapy for patients with advanced tumors who are not responding or under responding to the initial treatment according to the TNM classification (spermatomatoma and non-spermatomatoma), which are stage II to IV. Cervical pain FIGO Stage IV B Stage of cervical cancer (if the root treatment of this disease is not possible with surgery or radiotherapy) Palliative cisplatin / ifosfamide combined chemotherapy (alone use: no other combination drugs) One as an alternative to palliative care. Breast cancer is used for the palliative treatment of advanced refractory or recurrent breast cancer. Non-small cell lung cancer is used alone or in combination with chemotherapy for patients with inoperable or metastatic tumors. Small cell lung cancer is used in combination with chemotherapy. Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma) is used for single or combined chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard treatment, and it is used for separate or combined chemotherapy of other soft tissue sarcomas after surgery or radiotherapy failure. Ewing's sarcoma is used in combination chemotherapy after initial failure of a cytostatic agent. Non-Hodgkin's lymphoma is used in combination chemotherapy for patients with highly malignant non-Hodgkin's lymphoma who do not respond or do not respond to the initial treatment. Combination therapy for patients with recurrent tumors. Hodgkin's lymphoma is used to treat patients with Hodgkin's lymphoma who have developed early or early recurrence (the duration of complete remission is less than one year) after initial chemotherapy or chemotherapy and chemotherapy failure. Implemented within the framework of the case. Special Note: If cystitis accompanied by microscopic hematuria or gross hematuria occurs during the treatment of this product, the administration should be suspended until the patient's condition returns to normal.

Ifosfamide for injection, testicular tumors are used in combination with chemotherapy for patients with advanced tumors who are not responding or under responding to the initial treatment according to the TNM classification (spermatomatoma and non-spermatomatoma), which are stage II to IV. Cervical pain FIGO Stage IV B Stage of cervical cancer (if the root treatment of this disease is not possible with surgery or radiotherapy) Palliative cisplatin / ifosfamide combined chemotherapy (alone use: no other combination drugs) One as an alternative to palliative care. Breast cancer is used for the palliative treatment of advanced refractory or recurrent breast cancer. Non-small cell lung cancer is used alone or in combination with chemotherapy for patients with inoperable or metastatic tumors. Small cell lung cancer is used in combination with chemotherapy. Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma) is used for single or combined chemotherapy of rhabdomyosarcoma or osteosarcoma after failure of standard treatment, and it is used for separate or combined chemotherapy of other soft tissue sarcomas after surgery or radiotherapy failure. Ewing's sarcoma is used in combination chemotherapy after initial failure of a cytostatic agent. Non-Hodgkin's lymphoma is used in combination chemotherapy for patients with highly malignant non-Hodgkin's lymphoma who do not respond or do not respond to the initial treatment. Combination therapy for patients with recurrent tumors. Hodgkin's lymphoma is used to treat patients with Hodgkin's lymphoma who have developed early or early recurrence (the duration of complete remission is less than one year) after initial chemotherapy or chemotherapy and chemotherapy failure. Implemented within the framework of the case. Special Note: If cystitis accompanied by microscopic hematuria or gross hematuria occurs during the treatment of this product, the administration should be suspended until the patient's condition returns to normal.

Drug Name

Ifosfamide for injection

Drug type

Occupational injury medical insurance

Use classification

Cytotoxic drugs

Ifosfamide for injection

The main ingredient of this product is ifosfamide.
Chemical name: 3- (2-chloroethyl) -2-[(2-chloroethyl) amino] tetrahydro-2H-1,3,2-oxaphosphon-2-oxide.
Its structural formula:

Molecular formula: C ₇ H ₁₅ Cl ₂ N ₂ O ₂ P
Molecular weight: 261.10
Excipients: None

Ifosfamide properties for injection

This product is white crystal or crystalline powder.

Ifosfamide indications for injection

Testicular tumors are used in combination chemotherapy for patients with advanced tumors that do not respond to or fail to respond to the initial treatment according to the TNM classification (spermatoma and non-spermatoma), which are stage II to IV.
Cervical pain FIGO Stage IV B Stage of cervical cancer (if the root treatment of this disease is not possible with surgery or radiotherapy) Palliative cisplatin / ifosfamide combined chemotherapy (alone use: no other combination drugs) One as an alternative to palliative care.
Breast cancer is used for the palliative treatment of advanced refractory or recurrent breast cancer.
Non-small cell lung cancer is used alone or in combination with chemotherapy for patients with inoperable or metastatic tumors.
Small cell lung cancer is used in combination with chemotherapy.
Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma)
Single or combined chemotherapy for rhabdomyosarcoma or osteosarcoma after failure of standard treatment, and separate or combined chemotherapy for other soft tissue sarcomas after surgery or radiotherapy failure.
Ewing's sarcoma is used in combination chemotherapy after initial failure of a cytostatic agent.
Non-Hodgkin's lymphoma is used in combination chemotherapy for patients with highly malignant non-Hodgkin's lymphoma who do not respond or do not respond to the initial treatment. Combination therapy for patients with recurrent tumors.
Hodgkin's lymphoma is used to treat patients with Hodgkin's lymphoma who have developed early or early recurrence (the duration of complete remission is less than one year) after initial chemotherapy or chemotherapy and chemotherapy failure. Implemented within the framework of the case.
Special Note:
If cystitis with microscopic hematuria or gross hematuria occurs during the treatment of this product, the administration should be suspended until the patient's condition returns to normal.

Ifosfamide for injection specifications

1g.

Ifosfamide for injection usage and dosage

This product must be administered by an experienced oncologist, and appropriate dosage adjustments need to be made according to the individual circumstances of the patient. In adult monotherapy, the most commonly used method of administration is a divided administration schedule.
Split administration (30-120 minutes depending on the dose) generally uses ifosfamide at a daily dose of 1.2-2.4 g / m2 body surface area (BSA). The maximum is 60 mg / kg body weight, which is used continuously for 5 days as an intravenous infusion. This product can also be administered as a single large-dose continuous intravenous infusion for 24 hours. The dose is generally 5 g / m ² body surface lzu (125 mg / kg body weight) per course, which should not be higher than 8 g / m. 2Body surface area (200 mg / kg body weight). A single large dose of paint may cause more severe blood, urinary, renal, and central nervous system toxicity.
It should be noted that the concentration of ifosfamide infusion for humans should not exceed 4%. If used in combination with any other cytostatic drug, blood cell counts must be monitored before and during each chemotherapy cycle when using ifosfamide. The dosage used should be adjusted regularly based on blood signs.
Precautions:

When combined with other cellular bovine growth inhibitors as a combination chemotherapy, the dosage guidelines in the appropriate treatment regimen must be followed. When combined with other myelotoxic drugs, the dosage must be adjusted appropriately.
note:
Due to the urinary tract toxicity of ifosfamide, treatment with ifosfamide should often be combined with mesna. Mesna does not affect the efficacy and toxicity of ifosfamide. During cystitis with microscopic hematuria or gross hematuria during treatment, treatment should be temporarily suspended until normal.
Dosing method and treatment cycle:
This product should only be used by physicians with experience in oncology. The course of treatment can be repeated after 3-4 weeks. The interval should be adjusted according to the blood condition and other adverse reactions or accompanying symptoms.
Precautions:
Blood routine, renal function, urine routine and urine sediment should be monitored regularly. Considering the adverse effects on the central nervous system when combined with ifosfamide, antiemetics should be given in time. In case of fever and / or leukopenia, antibiotics and / or antifungals should be used prophylactically. Adequate diuretic measures and thorough oral hygiene are required.
Long-term treatment with ifosfamide requires adequate diuretic measures and routine monitoring of renal function. This should be especially true for children. In the event of renal disease, if continued treatment with ifosfamide, it must be estimated that there may be irreversible kidney damage and requires a careful assessment of the risk-benefit ratio. The following patients should follow the correct safety guidelines for the formulation of cytostatics when formulating and rosox [cf. M 620 Note for Guidance on Safe Handling of Cytotoxlc Anticancer Drugs issued by the German Health Care & Welfare Services ProfessionaIAssociation (BGW)].
To prepare a 4% isotonic injection, you only need to inject the double distilled water into the dry powder according to the different volume.

After adding the water, the dry powder is shaken vigorously, and after 1 / 2-1 minute, it dissolves quickly. If the drug does not completely dissolve immediately, leave the solution for several minutes to help dissolve. For intravenous infusion (about 20-120 minutes), the above prepared solution can be diluted in 250 ml of Ringer's solution (Ringer's Solution) or 5% glucose solution or 0.9% physiological saline. If the infusion time is more than 1-2 hours, it is recommended to dilute this solution in 500T¨a'J Ringer's solution, 5% fdi grape solution or 0.9% '4: Lg saline. For a 24-hour continuous infusion of ifosamine phosphate (such as 5 g / m ² ), the prepared ifosfamide solution needs to be diluted to 3000 ml with a 5% grape solution or 0.9% physiological saline.
pay attention:
As an alkylating agent, the product may induce mutations and even condense cancer. Avoid contact with skin and mucous membranes.
The following adverse reactions may occur in patients receiving roxoxane,

http://x1.webres.medlive.cn/drugref/ChemPreparationDetail/201306191745320252.jpg

Blood and bone marrow can cause different degrees of bone marrow damage (leukopenia, thrombocytopenia, anemia) with the size of the dose.
Leukopenia, secondary (possibly life-threatening) bacterial infections that may be accompanied by fever, reduced blood pressure, and increased risk of bleeding are common adverse reactions. The minimum appearance of white blood cells and platelets is usually one to two weeks after the start of treatment and is reversible within three to four weeks after the start of treatment. Anemia usually occurs after several treatment cycles. A high-dose regimen is more prone to leukopenia than a divided regimen. Patients who have received chemotherapy and / or radiation therapy and renal insufficiency will be very serious Bone marrow damage. As with most other oncology drugs, ifosfamide should be used for periodic haematological examinations. For example, the dose before the start of each chemotherapy and between the effects should be adjusted according to the haematology. See [Usage and Dosage] for dose adjustment for bone marrow damage.

Ifosfamide for injection adverse reactions

1. Myelosuppression: Leukopenia is more common than thrombocytopenia. The lowest value is 1 to 2 weeks after administration, and it usually recovers after 2 to 3 weeks. Has an effect on liver function. Gastrointestinal reactions: include loss of appetite, nausea, and vomiting, which usually disappear after 1 to 3 days of withdrawal.
2. Urinary tract reaction: can cause hemorrhagic cystitis, manifested as dysuria, frequent urination and dysuria, which can appear within hours or weeks after administration, usually disappear within a few days after discontinuation.
3. Central nervous system toxicity: dose-related, usually manifested as anxiety, panic, hallucinations and fatigue. Rarely, syncope, seizures, and even coma.
4. Rare transient asymptomatic liver and kidney dysfunction; if high-dose medication can cause metabolic acidosis due to renal toxicity. Rare cardiac and pulmonary toxicity.
5. Other reactions include hair loss, nausea and vomiting. Phlebitis can develop at the injection site.
6. Long-term medication can produce immunosuppression, hypopituitarism, infertility and secondary tumors.
Gastrointestinal nausea and vomiting are dose-related side effects, with more than 50% of cases having moderate to severe symptoms. Less appetite, diarrhea, constipation, and mucositis / stomatitis occur less frequently.
Renal and urinary tract disorders Hemorrhagic cystitis (visual and microscopic hematuria) are the more common ifosfamide dose-related side effects.
Common adverse reactions are renal tubular insufficiency, with high amino acid urine, phosphate urine, acid urine and proteinuria, or even Fanconi syndrome. This can cause rickets or osteomalacia (softening of the bones). Rarely, hypokalemia has been reported. Factors that induce proximal tubular insufficiency include previous unilateral nephrectomy (removal of one kidney), combined use of platinum-containing preparations, and concurrently receiving radiotherapy of the abdomen with the kidney or the remaining kidney.
Glomerular renal impairment with increased serum creatinine, decreased creatinine clearance, and proteinuria (protein in the urine) is an uncommon adverse reaction. The factors that induce glomerular renal insufficiency may be a single high-dose medication and a combination of platinum-containing preparations. Potential nephrotoxic drugs, such as nitroglycosides, acyclovir, and amphotericin B, must be used with caution. Although these drugs do not exacerbate damage to the renal tubules, they can further impair glomerular function. .
Severe kidney disease is an extremely rare adverse reaction. The predisposing factors are higher cumulative doses of the drug (total doses used since the start of treatment) and low age (especially children under 3 years of age). Therefore, the function of the glomeruli and tubules must be monitored and evaluated before, during and after treatment.
Precautions:
Split administration, hydration with 3 liters of fluid per day, and especially the simultaneous use of mesna can significantly reduce the number and severity of hemorrhagic cystitis. When receiving isoflavone famide treatment for a long time, we should pay attention to adequate diuresis and monitor whether the renal function is normal. Be especially careful with children. If kidney disease occurs, you should anticipate whether continued use of ifosfamide will cause irreversible damage to the kidney and carefully weigh the pros and cons,
Patients with unilateral nephrectomy, renal impairment, and previous treatment with nephrotoxic drugs (such as cisplatin) should be treated with caution because these patients have an increased chance and severity of myelotoxicity, nephrotoxicity, and cerebral toxicity.
10-20% of cases in the central nervous system may develop encephalopathy within hours to days of treatment. The risk factors for encephalopathy are poor general condition, impaired renal function (creatinine> 1.5 mg / dl), previous renal toxicity drugs (such as cisplatin), and post-renal obstruction (such as renal pelvic tumors). Other possible risk factors are aging, alcoholism, decreased plasma albumin and bicarbonate levels, liver insufficiency, or concurrently receiving high doses of antiemetic drugs. The most common symptoms of encephalopathy are dizziness, which can progress to lethargy and coma. Other symptoms of encephalopathy include weakness, forgetfulness, depression, disorientation, restlessness, confusion, hallucinations, cerebellar symptoms, urinary incontinence, and seizures. Under normal circumstances, encephalopathy symptoms are reversible, and usually disappear within a few days of stopping ifosfamide. Severe disease progression is extremely rare, and deaths have only been reported in high-dose cases. Split administration can reduce the incidence and severity of encephalopathy. Cases of visual impairment and dizziness are rare.
Hepatic liver adverse reactions are uncommon and liver dysfunction may occur with liver enzymes (such as SGOT SGPT, GGT) and / or elevated bilirubin.
Chronic interstitial pulmonary fibrosis and pneumonia may occur in the rare cases of the cardiovascular system and the lungs. One case of toxic allergic pulmonary edema has been reported. In rare cases, ventricular and supraventricular arrhythmias, ST-segment elevation, and heart failure have occurred following extreme doses of ifosfamide and / or prior or concomitant treatment with ring-shaped antibiotics (reported in this. In this case, routine electrolyte monitoring should be taken care of, and special attention should be given to patients who previously had heart disease.
Due to its mechanism of action, ifosfamide as an alkylating agent can cause (sometimes irreversibly) impaired spermatogenesis and lead to azoospermia and / or persistent oligospermia. Reports of irreversible ovarian dysfunction leading to amenorrhea and decreased female sex hormone levels are uncommon.
Secondary tumours. As is common with cytostatics, especially with alkylating agents, the use of ifosfamide may increase the risk of secondary tumours or precursors of advanced complications. Bladder cancer and myelodysplastic syndrome, which can eventually cause acute leukemia, are at increased risk.
Other adverse reactions to hair loss are another common side effect. According to the dosage and treatment interval. Hair loss may occur in 100% of patients, but it can be recovered.
In addition to the above, there may be another case of SIADH (adequate ADH secretion syndrome, Schwartz-Bartter sign) with hyponatremia and edema.
One other case developed acute pancreatitis.
A rare phlebitis or fever.
Polyneuropathy in another case,
A rare case of dermatitis and mucositis.
A rare case of an allergic reaction may develop fever or even shock in individual cases.
The response to radiotherapy intensified in another case.
Notes on monitoring of laboratory indicators:
Should be regular. Monitor blood (red blood cells, white blood cells, and platelets) daily if necessary until normal. Individuals should be evaluated for patients who have developed liver and / or kidney damage before treatment begins. Close monitoring of these patients is recommended during use and roxano treatment. Diabetic patients should be regularly checked for glucose metabolism to adjust anti-diabetic treatment in a timely manner when necessary.
Impact on the ability to drive and operate machines:
Ifosfamide may affect patients' ability to drive and operate machines. This may be directly caused by encephalopathy, especially when patients are taking drugs that affect the central nervous system or alcohol at the same time, or indirectly by nausea and vomiting.

Ifosfamide for injection contraindications

The following types of patients are disabled and Lok Seng:
-Known to be highly allergic to ifosfamide-severe myelosuppression (especially in patients who have previously received cytotoxic drugs and / or radiotherapy)
-Infection-renal insufficiency and / or urinary tract obstruction-cystitis-pregnancy (see related section)
A breastfeeding (see related section)

Precautions for ifosfamide for injection

Care should be taken to monitor possible central nervous system toxicities in patients receiving ifosfamide therapy. Once symptoms of encephalopathy appear, ifosfamide should be discontinued, and patients should not be re-administered even after they return to normal.
Before the treatment process begins. Problems such as urinary tract obstruction, cystitis, infection, and electrolyte imbalance should be ruled out or properly addressed first. As with other cytostatics, fragile, elderly, and previously radiotherapy patients should be used with care and roxox. Special attention should be paid to patients with poor immune function, such as diabetes, chronic liver disease and kidney disease. Patients with brain metastases, brain symptoms and / or renal impairment should be routinely monitored,
Ifosfamide is genetically toxic, and patients or their spouses should avoid conception during and within 6 months of treatment. Men may consider storing sperm before treatment begins. Women should not become pregnant during treatment. If pregnant during treatment, patients should seek genetic advice from a doctor. The duration of contraception after chemotherapy should be based on the progress of the disease and the fertility wishes of the patient's couple. It is also recommended to seek genetic advice first.

Ifosfamide for injection for pregnant and lactating women

If it must be used within the first three months of pregnancy, you need to decide whether to terminate the pregnancy, after the first three months of pregnancy. If treatment cannot be postponed and the patient wishes to retain the fetus, the patient should be made aware of the risk of teratogenicity before treatment can begin.

Ifosfamide for injection for children

According to the weight or body surface area to determine the dose, you can refer to the above usage and dosage.

Ifosfamide for injection

According to the weight or body surface area to determine the dose, you can refer to the above usage and dosage.

Ifosfamide Drug Interactions for Injection

Interactions with other drugs and other forms of interaction:
Bone marrow toxicity increases when combined with other cytostatics or radiotherapy. Ifosfamide may increase skin reactions caused by relapse therapy.
If the patient has or has received nephrotoxic drugs such as cisplatin, aminoglycosides, acyclovir or amphotericin B, the renal toxicity of ifosfamide will increase, followed by bone marrow toxicity and nerve (central (Nerve) toxicity can also increase.
Because ifosfamide suppresses the immune system, it may reduce the patient's response to the vaccine, and the damage caused by the vaccine will be exacerbated when the active vaccine is administered. Concomitant use with warfarin may increase the latter's anticoagulant effect and increase the risk of bleeding. Drugs that act on the central nervous system (such as antiemetics, sedatives, narcotics or antihistamines) should be used with caution or discontinued when necessary, especially in patients with brain tumors caused by ifosamine Similar to phosphoramide, ifosfamide may interact with:
Allopurinol and hydrochlorothiazide may aggravate its bone marrow inhibitory toxicity. Chlorpromazine, triiodothyroxine, and acetaldehyde dehydrogenase inhibitors such as disulfiram can enhance its efficacy and toxicity.
Hexan can increase the hypoglycemic effect of sulfa drugs.
If you have used phenobarbital, phenytoin, chloral hydrate before or at the same time, you have the risk of inducing liver microsomal enzymes.
Hexen can strengthen the muscle relaxation effect of succinylcholine chloride.
Because a substance in grapefruit may affect the activation of ifosfamide and reduce its therapeutic effect, patients must avoid eating or drinking grapefruit and grapefruit juice.

Ifosfamide overdose for injection

Because ifosfamide does not have a specific antidote, the drug is particularly cautious each time it is administered. In the treatment of ifosfamide suicide, accidental overdose or poisoning
Hemodialysis can be performed. When overdose is used, the most common adverse reaction is myelosuppression. Mainly manifested as leukopenia. The duration and severity of bone marrow transplantation is related to the degree of drug overdose, and blood monitoring and the general condition of the patient need to be monitored frequently. If severe neutropenia occurs, inflammation prevention is needed, and sufficient antibiotics are needed to treat the infection. If thrombocytopenia occurs, supplement platelets as needed. Severe hemorrhagic cystitis can occur if it is not prevented or inadequately prevented.
If Ifosfamide-related encephalopathy occurs, the use of methylene blue can be considered.
Precautions:
Because ifosfamide's cytostatic effect occurs only after activation by the liver, there is no danger of damaging the tissue if it occurs accidentally next to the vein.

Ifosfamide clinical trials for injection

A randomized, non-blind study of cervical cancer treatment compared 151 cisplatin (50 mg / m ² every 3 weeks) doses with ifosfamide (5 g / mZ every 33 weeks) in 151 women with FIGO stage IVB cervical cancer Gemex sodium 6 g / mz) 6 cycles of combined therapy and cisplatin 50 mg / m2 every 3 weeks at a dose of 6 cycles of monotherapy, the results show that compared to monotherapy, the combination therapy has statistical Significantly higher response rates (31.1% vs. 17.8% p = 0.004) and longer progression-free survival (4.6 months vs. 3.2 months. P = 0.003). No effect on overall survival was shown. Combination therapy is also accompanied by higher toxicity (leukopenia, nephrotoxicity, peripheral neurotoxicity, and central nervous system toxicity).
Hodgkin's disease is treated again and the remission rate (after the failure of the first treatment) has not been evaluated in randomized studies. Based on the results of open trials, the rate of irrigated cases is about 20%, while the early relapse cases after complete remission are About 30%.

Ifosfamide for injection pharmacology and toxicology

Preclinical safety data The LDo (intraperitoneal injection) dose range for acutely poisoned mice is 520-760 mg / kg, while for rats it is 150-300 mg / kg. Repeated intravenous administration of doses of 100 mg / kg or higher may cause symptoms of poisoning in rats.
Chronic poisoning is consistent with clinical adverse reactions. Chronic poisoning tests have shown damage to the lymphohematopoiesis, gastrointestinal tract, bladder, kidney, liver, and gonads.
Mutagenic and carcinogenic As an alkylating agent, ifosfamide is a genotoxic substance and has corresponding mutagenicity. Ifosfamide has been shown to have a carcinogenic effect in long-term studies in rats and mice.
Reproductive toxicity ifosfamide has embryotoxicity and teratogenic effects. Teratogenic effects were observed in three animals (mouse, rat, rabbit) at a dose of 3-7.5 mg / kg.
Pharmacodynamics Ifosfamide is a cell growth inhibitor belonging to the oxazaphos ring family. Chemically, it is related to nitrogen mustard and is a synthetic analog of cyclophosphamide. Cyclophosphamide is inactive in vitro and is selectively activated in the liver by microsomal enzymes. At the same time, the oxygen, nitrogen, phosphorus ring C-4 yard of this product is hydroxylated. As a result, its primary metabolite, 4-hydroxymonoisophosphamide, is formed and is in equilibrium with its isomer, isoaldehyde phosphate ifosfamide. Ifaldehyde ifosfamide develops into acrolein and alkylated metabolite ifosfamide mustard. Acrolein is the main cause of ifosfamide toxicity. Another metabolic pathway is the oxidation and dealkylation of vinyl chloride side chains. Ifosfamide's cytotoxic effect is due to the interaction between its alkylated metabolites and DNA. The selected attack point is the phosphodiester bond of DNA. Alkylation results in the breaking and cross-linking of DNA strands. In the cell cycle, passage through the G2 phase is blocked. Its cytotoxicity is not cell cycle-specific, and cross-resistance to this product cannot be ruled out, mainly referring to its structure-related cell growth inhibitors such as cyclophosphamide. But other alkylating agents are also included. On the other hand, ifosfamide has been reported to be resistant to cyclophosphamide or tumors that recur after cyclophosphamide treatment are often still effective.

Ifosfamide for injection pharmacokinetics

There is a linear relationship between the dose and the plasma drug concentration. The plasma protein binding rate is low. The volume of distribution is approximately equivalent to the total volume of fluid throughout the body, and ifosfamide can be detected in various organs and tissues within minutes after intravenous administration. Untransformed ifosfamide may cross the blood-brain barrier, and its active metabolites are still controversial; there is no proven data that ifosfamide can pass through the placental barrier or be secreted into milk. Since this product has been confirmed to be teratogenic in animal experiments, and the structural similarity between this product and cyclophosphamide, the possibility that ifosfamide will also pass through the placental barrier and be secreted into milk must be estimated. Ifosfamide and its 4-hydroxy-metabolites generally have plasma half-life of 4-7 hours. They are excreted mainly through the kidneys. When dosed at a dose of 1.6-2.4 g / m ² / day for 3 consecutive days, 57% of the dose was excreted as a metabolite or unconverted ifosfamide within 72 hours: at 3.8-5 g / When a single large dose of mZ was administered, 80% of the administered dose was excreted in the form of metabolites or untransformed ifosfamide within 72 hours. The excretion of the untransformed drugs at the above doses reached 15% and 53% respectively .

Ifosfamide for injection storage

Store below 25 ° C.

Ifosfamide for injection

Colorless glass bottle with grey rubber stopper, 1 bottle / box

Ifosfamide for injection

60 months.

Ifosfamide for injection

Import Drug Registration Standard: JX20080219

^[1]